Abstract

To assess the clinical efficacy of salvia polyphenolic acid in the recovery of ischemic stroke. This randomized controlled trial recruited 80 patients with ischemic stroke treated in our hospital from September 2021 to June 2022 and assigned them to receive either aspirin enteric tablets and atorvastatin calcium tablets (control group) or aspirin enteric tablets and simvastatin tablets plus salvia polyphenolic acid (observation group), with 40 cases in each group. The primary endpoint was clinical efficacy and the secondary endpoints included neurological function, disease recovery, limb and cognitive function and quality of life. Patients with salvia polyphenolic acid had significantly higher clinical efficacy than those without (p<0.05). Salvia polyphenolic acid resulted in significantly lower national institutes of health stroke scale scores and higher ability of daily living scores in patients vs. routine management (p<0.05). Patients in the observation group showed significantly higher Fugl-Meyer and Montreal cognitive assessment scores and World Health Organization quality of life brief version scores than those in the control group (p<0.05). Salvia polyphenolic acid significantly ameliorates the stroke status of ischemic stroke patients, promotes the recovery of neurological functions, significantly enhances the patient’s living ability and therapeutic effects, and optimizes the patient’s limb and cognitive functions, thus effectively improving the quality of life and promoting the patient’s recovery.